The company has substantially boosted the progress of a novel therapy for cardiac amyloidosis, employing the compound. Initial trial information suggests potential improvements for patients diagnosed from a severe https://bridgebio786583.link4blogs.com/62985970/bridgebio-progresses-amyloidosis-management-using-the-therapy